// App-Quantinova.ai

9000 : Progression After the Next Line of Therapy (PFS2) and Updated OS Among Patients with Advanced NSCLC and PD-L1 TPS >=50% enrolled in KEYNOTE-024

Researchers

Presenter

  • Julie R. Brahmer

Principal Investigators

  • Delvys Rodriguez-Abreu

  • Andrew George Robinson

  • Rina Hui

  • Tibor Csoszi

  • Andrea Fulop

  • Maya Gottfried

  • Nir Peled

  • Ali Tafreshi

  • Sinead Cuffe

  • Mary O'Brien

  • Suman Rao

  • Katsuyuki Hotta

  • Melanie A. Leiby

  • Jessica McLean

  • Yue Shentu

  • Reshma A. Rangwala

  • Martin Reck

Medical Centers

  • The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD

  • Hospital Universitavio Insular De Gran Canaria, Las Palmas, Spain

  • Cancer Centre Of Southeastern Ontario, Kingston, ON, Canada

  • Westmead Hospital and University of Sydney, Sydney, Australia

  • Jasz-Nagykun-Szolnok County Hospital, Szolnok, Hungary

  • Orszagos Koranyi TBC es Pulmonologiai Intezet, Budapest, Hungary, Budapest, Hungary

  • Meir Medical Center, Kfar-Saba, Israel

  • Davidoff Cancer Center, Petach Tiqwa, Israel

  • Southern Medical Day Care Centre, Wollongong, Australia

  • St. Jamess Hospital and Cancer Trials Ireland (formerly ICORG All Ireland Cooperative Oncology Research Group), Dublin, Ireland

  • Royal Marsden Hospital, Surrey, United Kingdom

  • MedStar Franklin Square Hospital, Baltimore, MD

  • Okayama University Hospital, Okayama, Japan

  • Merck & Co., Inc., Kenilworth, NJ

  • Lung Clinic Grosshansdorf, Airway Research Center North (ARCN), member of the German Center for Lung Research (DZL), Grosshansdorf, Germany

Locations

  • Canada

  • Ireland

  • Japan

  • Spain

  • Germany

  • United Kingdom

  • Australia

  • United States

  • Israel

  • Hungary

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Programmed death-ligand 1

  • Tissue polypeptide-specific antigen

Drug/Treatment

  • Pemetrexed

  • Pembrolizumab

Outcome

  • N/A

Study Design

  • Cross Over

Phase

  • NA

Study Id's

  • NCT02142738

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved